WHAT IS CLAIMED IS:

1. Use of an anti-PD-1 antibody, or antigen binding fragment thereof in the manufacture of a medicament for treating cancer in a human patient, wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises:

(a) light chain complementarity determining regions (CDRs) comprising a sequence of amino acids as set forth in SEQ ID NOs: 1, 2 and 3 and heavy chain CDRs comprising a sequence of amino acids as set forth in SEQ ID NOs: 6, 7 and 8; or

(b) light chain CDRs comprising a sequence of amino acids as set forth in SEQ ID NOs: 11, 12 and 13 and heavy chain CDRs comprising a sequence of amino acids as set forth in SEQ ID NOs: 14, 15 and 16, and

wherein about 400 mg of the anti-PD-1 antibody or antigen-binding fragment thereof is to be administered to the patient every approximately six weeks.

2. The use of claim 1, wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises:

(a) a heavy chain variable region comprising a sequence of amino acids as set forth in SEQ ID NO:9, or a variant of SEQ ID NO:9, and

(b) a light chain variable region comprising:

(i) a sequence of amino acids as set forth in SEQ ID NO:4, or a variant of SEQ ID NO:4,

(ii) a sequence of amino acids as set forth in SEQ ID NO:22, or a variant of SEQ ID NO:22, or

(iii) a sequence of amino acids as set forth in SEQ ID NO:23, or a variant of SEQ ID NO:23.

3. The use of claim 1 or 2, wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a sequence of amino acids as set forth in SEQ ID NO:9 and a light chain variable region comprising a sequence of amino acids as set forth in SEQ ID NO:4.

4. The use of claim 1 or 2, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is a monoclonal antibody comprising:

(a) a heavy chain comprising a sequence of amino acids as set forth in SEQ ID NO:10, or a variant of SEQ ID NO:10, and

(b) a light chain comprising a sequence of amino acids as set forth in SEQ ID NO:5, a variant of SEQ ID NO:5, SEQ ID NO:24, a variant of SEQ ID NO:24, SEQ ID NO:25, or a variant of SEQ ID NO:25.

5. The use of any of claims 1-4, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is a monoclonal antibody comprising a heavy chain comprising a sequence of amino acids as set forth in SEQ ID NO:10 and a light chain comprising a sequence of amino acids as set forth in SEQ ID NO:5.

6. The use of any of claims 1-5, wherein the cancer is selected from the group consisting of: melanoma, non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular cancer, non-Hodgkin lymphoma, renal cancer, Hodgkin lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, endometrial cancer, squamous cell carcinoma, or salivary cancer.

7. The use of any of claims 1-6, wherein the patient has a tumor with a high mutational burden.

8. The use of any of claims 1-5, wherein the patient has a microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumor.

9. The use of any of claims 1-5, wherein the cancer is unresectable or metastatic melanoma.

10. The use of any of claims 1-5, wherein the cancer is metastatic non-small cell lung cancer (NSCLC).

11. The use of any of claims 1-5, wherein the cancer is recurrent or metastatic head and neck squamous cell cancer (HNSCC).

12. The use of any of claims 1-5, wherein the cancer is (1) refractory classical Hodgkin lymphoma (cHL), or (2) cHL and the patient has relapsed after 3 or more lines of therapy for cHL.

13. The use of any of claims 1-5, wherein the cancer is locally advanced or metastatic urothelial carcinoma.

14. The use of any of claims 1-5, wherein the cancer is locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.

15. The use of any of claims 1-5, wherein the cancer is cervical cancer.

16. The use of any of claims 1-5, wherein the cancer is primary mediastinal large B-cell lymphoma (PMBCL).

17. The use of any of claims 1-5, wherein the cancer is resected high-risk stage III melanoma.

18. The use of any of claims 1-5, wherein the cancer is hepatocellular carcinoma.

19. The use of any of claims 1-5, wherein the cancer is renal cell carcinoma (RCC).

20. The use of any of claims 1-5, wherein the cancer is recurrent, locally advanced or metastatic Merkel cell carcinoma (MCC).

21. The use of any of claims 1-20, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is pembrolizumab.

22. A composition comprising about 400 mg of pembrolizumab and a pharmaceutically acceptable carrier.

23. The composition of claim 22, further comprising 10 mM histidine, pH 5.5, 7% sucrose, and 0.02% polysorbate 80.

24. A kit for treating a patient with cancer, the kit comprising:

(a) about 400 mg of an anti-PD-1 antibody or antigen binding fragment thereof, and

(b) instructions for using the anti-PD-1 antibody or antigen binding fragment thereof, in the use of any of claims 1-20.

25. The kit of claim 24, wherein the anti-PD-1 antibody is pembrolizumab.

26. Use of the composition of any of claims 22-23 in the manufacture of a medicament for treating an individual suffering from cancer.

27. The use of claim 26 or the kit of claim 24 or 25, wherein the cancer is melanoma, lung cancer, head and neck cancer, bladder cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular cancer, lymphoma, renal cancer, mesothelioma, ovarian cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, endometrial cancer, squamous cell carcinoma, or salivary cancer.

28. The use of any of claims 1-5, wherein the cancer is endometrial cancer.